James Lynam

Tumour-agnostic immunotherapy: aligning biological rationale, biomarker precision, and real-world implementation

Summary Tumour-agnostic immunotherapy has reshaped precision oncology by showing that treatment benefit can, in selected settings, be predicted by a shared biological state rather than anatomical origin. Microsatellite instability-high or mismatch repair-deficient cancer is the clearest example, with durable responses...